Scientists track cancer drug in blood to predict treatment success
NCT ID NCT04557007
Summary
This study aimed to understand how the amount of pembrolizumab (an immunotherapy drug) in patients' blood relates to their treatment outcomes. Researchers monitored 80 people with advanced non-small cell lung cancer who were receiving pembrolizumab, either alone or with chemotherapy, for the first time. By measuring drug levels and immune cell activity in blood samples, they hoped to learn if these measurements could help predict how well the treatment would work.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St Olavs University Hospital
Trondheim, Norway
Conditions
Explore the condition pages connected to this study.